We observed comparable competitive behaviour using an alternative AR-positive prostate cancer cell line, LNCaP, and determined a Ki value for the Enzalutamide-AR interaction within LNCaP cells in a similar range to the one measured in CWR22Pc-R1-AD1 cells (Supplementary Fig. S3). This evidence concerns the gene AR and prostate carcinoma.